ACCREDITED BY UEMS WITH 3 ECMEC CREDITS
AVAILABLE IN ENGLISH, GERMAN, SPANISH, AND FRENCH
The rising prevalence of chronic lymphocytic leukemia (CLL) underscores the critical need for predictive and prognostic biomarkers. However, the vast and ever-evolving landscape of biomarkers can present challenges for physicians when integrating them into CLL management.
Led by global key opinion leaders, this UEMS-accredited course (3 ECMEC credits) offers practical insights and the latest data from major medical conferences. Participants will review current CLL treatments and explore future trends, with a deep dive into the importance of predictive and prognostic biomarkers in guiding treatment decisions. Additionally, you'll explore the significance of measurable residual disease (MRD) assessment, including its methodological considerations. The course also includes clinical case analyses to help you apply these concepts in practice.
Course Highlights:
➡️ Overview of CLL treatment and future perspectives
➡️ Detailed exploration of CLL biomarkers: prognostic and predictive
➡️ Importance of MRD in CLL outcomes and available assessment methods
➡️ Clinical case discussions for practical application
Enroll now for free to enhance your expertise in precision haematology and earn 3 ECMEC credits accredited by UEMS, ensuring improved patient outcomes in CLL management 👉 [ Ссылка ]
This activity is supported by an Independent Medical Education grant from MSD.
___________
Haematology, CLL, chronic lymphocytic leukemia, biomarkers, predictive biomarkers, prognostic biomarkers, CLL treatment, MRD, measurable residual disease, BTK inhibitors, BCL-2 antagonists, CLL guidelines, precision medicine, clinical case studies, medical education, UEMS accredited, 3 ECMEC credits, EN, DE, ES, FR
